Wisconsin is currently home to 1280 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block
NCT04559425
Recruiting
Few studies are specifically designed to address health concerns that are already relevant during pregnancy. The consequence is a lack of evidence on best clinical practice. This includes mothers and their babies when pregnancy is complicated by an abnormally slow heart rate due to maternal antibody-mediated heart disease in the unborn baby (fetus). Since the late seventies, it has been possible to detect and monitor fetal disease by ultrasound images and to treat selected conditions with pharma... Read More
Gender:
FEMALE
Ages:
Between 16 years and 50 years
Trial Updated:
05/21/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Heart Block Complete, Heart Block Second Degree
Register for Updates
Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia
NCT03376438
Recruiting
The FAST Trial Registry is a prospective observational cohort study of fetuses with a new diagnosis of atrial flutter (AF) or supraventricular tachycardia (SVT) that is severe enough to consider prenatal treatment (see eligibility criteria below). Aims of the Registry include to establish a large clinical database to determine and compare the efficacy and safety of different prenatal treatment strategies including observation without immediate treatment, transplacental antiarrhythmic fetal treat... Read More
Gender:
FEMALE
Ages:
Between 16 years and 50 years
Trial Updated:
05/21/2024
Locations: Children's Hospital of Wisconsin, Milwaukee, Wisconsin
Conditions: Atrial Flutter, Tachycardia, Supraventricular, Tachycardia, Atrial Ectopic, Tachycardia, Reciprocating, Tachycardia Atrial, Tachycardia, Atrioventricular Nodal Reentry, Tachycardia, Paroxysmal, Fetal Hydrops
Register for Updates
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
NCT05390892
Recruiting
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
05/20/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Type2Diabetes, ASCVD
Register for Updates
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis
NCT05301101
Recruiting
This trial applies a uniform approach to re-irradiation for planning and diagnostic image fusion, dose summation, dose calculations, and follow up for tumor control and detailed toxicity analysis of serial Organs At Risk (OARs). Serial organs include named arteries and nerves, spinal cord, and gastrointestinal tract.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Froedtert Hospital, Milwaukee, Wisconsin
Conditions: Solid Tumor
Register for Updates
GCC Agonist Signal in the Small Intestine
NCT05107219
Recruiting
This early phase I trial studies the guanylyl cyclase C (GCC) agonist effect on cGMP signal in duodenal tissue. Plecanatide and linaclotide are drugs approved by the Food and Drug Administration for the treatment of conditions related to constipation. This trial aims to see the effects of taking either one of two drugs, plecanatide or linaclotide, or no drug, on a certain chemical found in the tissue collected from small intestine and how they compare.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
Conditions: Barrett Esophagus, Gastroesophageal Reflux Disease, Malignant Digestive System Neoplasm
Register for Updates
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT04373564
Recruiting
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x-ray, CT-scan or MRI investigations, doctors are using contrast media (a kind of dye) which can be given to patients by injection into a blood vessel or by mouth. In this study researchers want to find out whether so called gadolinium-based contrast agents (G... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/15/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Motor Function, Cognitive Function, Contrast Media
Register for Updates
Pulmonary Hypertension Association Registry
NCT04071327
Recruiting
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH a... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
05/14/2024
Locations: University of Wisconsin Hospital and Clinics, Madison, Wisconsin
Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
Register for Updates
Study of DF9001 in Patients With Advanced Solid Tumors
NCT05597839
Recruiting
DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Solid Tumor, Adult
Register for Updates
Oxytocin and Fetal Heart Rate Changes
NCT03232918
Recruiting
The reported risk of nonreassuring fetal heart trace following neuraxial analgesia is 3-23%. This variability may be due to fluid and oxytocin management prior to and during the initiation of neuraxial analgesia. The study hypothesis is that decreasing the oxytocin infusion rate by 50 % prior to initiation of combined spinal epidural analgesia will cause a reduction in the incidence of adverse fetal heart rate changes.
Gender:
FEMALE
Ages:
Between 18 years and 55 years
Trial Updated:
05/13/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Fetal Bradycardia Complicating Labor and Delivery, Fetal Bradycardia During Labor, Fetal Heart Rate or Rhythm Abnormality Affecting Fetus
Register for Updates
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
NCT05813678
Recruiting
This is a 10-year multi-center, global, observational study to further characterize the safety profile of pegvaliase, including hypersensitivity reactions, long-term safety and tolerability, and the effectiveness of the additional risk minimization measures (aRMMs) (European Union (EU) only) in subjects receiving pegvaliase for the treatment of PKU. Subjects for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enroll... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/10/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Phenylketonuria (PKU)
Register for Updates
Testing Two Interventions to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV
NCT06269081
Recruiting
Engagement in HIV medical care and adherence to HIV medications are both essential in improving health outcomes among people living with HIV (PLH), but PLH living in rural areas-who suffer higher mortality rates than their urban counterparts-can confront multiple barriers to care engagement and adherence, especially as they face the logistical, medical, and social challenges associated with aging. This project will test the efficacy of two interventions to determine their impact on HIV health ou... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/09/2024
Locations: Center for AIDS Intervention Research, Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: HIV
Register for Updates
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224
Recruiting
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Register for Updates